Clinical Trial

A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus

Name: A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus — clinical trial record (NCT07303803)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CHIG-MASH

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This trial aims to evaluate the efficacy and safety of chiglitazar as a combination therapy for patients with MASH and T2DM.

Protocol Amendment History 1 change

critical Recruitment opened 2026-06-04

Trial Details

NCT Number	NCT07303803
Lead Sponsor	Shanghai Jiao Tong University School of Medicine Collaborators: Chipscreen Biosciences, Ltd.
Conditions	MASH - Metabolic Dysfunction-Associated Steatohepatitis, T2DM (Type 2 Diabetes Mellitus)
Enrollment	300 participants
Start Date	2026-01-01
Primary Completion	2030-12-01 (estimated)
Study Completion	2030-12-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-03